User login
Key clinical point: Atogepant was an effective and safe treatment option for the prevention of episodic migraine.
Major findings: Atogepant (10 mg, 30 mg, and 60 mg) vs placebo led to a significant reduction in monthly migraine days (MMDs; P < .001, P < .001, and P = .0009, respectively), monthly headache days (all P < .001), acute medication use (all P < .001), as well as increase in the proportion of patients achieving a ≥50% reduction in MMDs (P = .007, P = .02, and P = .003, respectively). No significant difference was observed in serious adverse events between the atogepant and placebo groups.
Study details: This meta-analysis of six randomized controlled trials included 4569 patients with episodic migraine who were randomly assigned to receive atogepant (10 mg, 30 mg, or 60 mg) or placebo.
Disclosure: The study did not receive funding from any sources. The authors declared no conflicts of interest.
Source: Alrasheed AS, Almaqboul TM, Alshamrani RA, AlMohish NM, Alabdali MM. Safety and efficacy of atogepant for the preventive treatment of migraines in adults: A systematic review and meta-analysis. J Clin Med. Published online November 08, 2024. Source
Key clinical point: Atogepant was an effective and safe treatment option for the prevention of episodic migraine.
Major findings: Atogepant (10 mg, 30 mg, and 60 mg) vs placebo led to a significant reduction in monthly migraine days (MMDs; P < .001, P < .001, and P = .0009, respectively), monthly headache days (all P < .001), acute medication use (all P < .001), as well as increase in the proportion of patients achieving a ≥50% reduction in MMDs (P = .007, P = .02, and P = .003, respectively). No significant difference was observed in serious adverse events between the atogepant and placebo groups.
Study details: This meta-analysis of six randomized controlled trials included 4569 patients with episodic migraine who were randomly assigned to receive atogepant (10 mg, 30 mg, or 60 mg) or placebo.
Disclosure: The study did not receive funding from any sources. The authors declared no conflicts of interest.
Source: Alrasheed AS, Almaqboul TM, Alshamrani RA, AlMohish NM, Alabdali MM. Safety and efficacy of atogepant for the preventive treatment of migraines in adults: A systematic review and meta-analysis. J Clin Med. Published online November 08, 2024. Source
Key clinical point: Atogepant was an effective and safe treatment option for the prevention of episodic migraine.
Major findings: Atogepant (10 mg, 30 mg, and 60 mg) vs placebo led to a significant reduction in monthly migraine days (MMDs; P < .001, P < .001, and P = .0009, respectively), monthly headache days (all P < .001), acute medication use (all P < .001), as well as increase in the proportion of patients achieving a ≥50% reduction in MMDs (P = .007, P = .02, and P = .003, respectively). No significant difference was observed in serious adverse events between the atogepant and placebo groups.
Study details: This meta-analysis of six randomized controlled trials included 4569 patients with episodic migraine who were randomly assigned to receive atogepant (10 mg, 30 mg, or 60 mg) or placebo.
Disclosure: The study did not receive funding from any sources. The authors declared no conflicts of interest.
Source: Alrasheed AS, Almaqboul TM, Alshamrani RA, AlMohish NM, Alabdali MM. Safety and efficacy of atogepant for the preventive treatment of migraines in adults: A systematic review and meta-analysis. J Clin Med. Published online November 08, 2024. Source